Start an analysis for DLB
Dolby Laboratories, Inc.
Stock · NYSEProgram summary
| Field | Value | As of | Source |
|---|---|---|---|
| Current authorization | $700m | 25-Sep-26 | 10-K filed 17-Nov-26 |
| Remaining authorization | $362m | 25-Sep-26 | 10-K filed 17-Nov-26 |
| Program expiry | n/a | — | |
| Repurchased last quarter | $65m | 25-Sep-26 | 10-K filed 17-Nov-26 |
| Has used an ASR | No | — |
Programs
| Authorized on | Authorized | Remaining | Expires | Terms |
|---|---|---|---|---|
| Not found in filings | $350m | $12mEST | n/a | Fiscal 2024: August 2024 350,00010-K filed 17-Nov-26 |
| Not found in filings | $350m | $350mEST | n/a | Fiscal 2026: July 2026 350,00010-K filed 17-Nov-26 |
Open-market repurchases
- Jul ’26
- Aug ’26
- Sep ’26
| Month ended | Shares | Avg price | ≈ Value | Source |
|---|---|---|---|---|
| 25-Sep-26 | 601,162 | $61.61 | $37m | 10-K filed 17-Nov-26 |
| 21-Aug-26 | 453,220 | $61.70 | $28m | 10-K filed 17-Nov-26 |
| 24-Jul-26 | 0 | — | $0 | 10-K filed 17-Nov-26 |